Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral Covid-19 Hospital

View through CrossRef
AbstractIntroductionAntibody response play a fundamental role in the natural history of infectious disease. A better understanding of the immune response in patients with SARS-CoV-2 infection could be important for identifying patients at greater risk of developing a more severe form of disease and with a worse prognosis.MethodsWe performed a cross-sectional analysis to determine the presence and the levels of both anti-SARS-CoV-2 IgG and IgA in a cohort of hospitalized patients with confirmed infection at different times in the natural history of the disease. Patients enrolled when admitted at the emergency department were prospectively followed up during hospital stay.ResultsOverall, 131 patients were considered with a total of 237 samples processed. Cross-sectional analysis showed that seroconversion for IgA seems to occur between days 5 and 15 while IgG response seems to occur slightly later, peaking at day 20 after symptoms onset. Both IgA and IgG were maintained beyond two months. Severe patients showed a higher IgA response compared with mild patients when analyzing optical density (8.3 versus 5.6, p < 0.001). Prospective analysis conducted on 55 patients confirmed that IgA appear slightly earlier than IgG. After stratifying for the severity of disease, both the IgA and IgG response was more vigorous in severe cases. Moreover, while IgG tended to stabilize, there was a relevant decline after the first month of IgA levels in mild cases.ConclusionIgA and IgG antibody response is closely related although seroconversion for IgA occurs earlier. Both IgA and IgG are maintained beyond two months. Severe patients showed a more vigorous IgA and IgG response. IgA levels seem to decline after one month since the onset of symptoms in mild cases.
Title: Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral Covid-19 Hospital
Description:
AbstractIntroductionAntibody response play a fundamental role in the natural history of infectious disease.
A better understanding of the immune response in patients with SARS-CoV-2 infection could be important for identifying patients at greater risk of developing a more severe form of disease and with a worse prognosis.
MethodsWe performed a cross-sectional analysis to determine the presence and the levels of both anti-SARS-CoV-2 IgG and IgA in a cohort of hospitalized patients with confirmed infection at different times in the natural history of the disease.
Patients enrolled when admitted at the emergency department were prospectively followed up during hospital stay.
ResultsOverall, 131 patients were considered with a total of 237 samples processed.
Cross-sectional analysis showed that seroconversion for IgA seems to occur between days 5 and 15 while IgG response seems to occur slightly later, peaking at day 20 after symptoms onset.
Both IgA and IgG were maintained beyond two months.
Severe patients showed a higher IgA response compared with mild patients when analyzing optical density (8.
3 versus 5.
6, p < 0.
001).
Prospective analysis conducted on 55 patients confirmed that IgA appear slightly earlier than IgG.
After stratifying for the severity of disease, both the IgA and IgG response was more vigorous in severe cases.
Moreover, while IgG tended to stabilize, there was a relevant decline after the first month of IgA levels in mild cases.
ConclusionIgA and IgG antibody response is closely related although seroconversion for IgA occurs earlier.
Both IgA and IgG are maintained beyond two months.
Severe patients showed a more vigorous IgA and IgG response.
IgA levels seem to decline after one month since the onset of symptoms in mild cases.

Related Results

Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays
Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays
ABSTRACTThe COVID-19 pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread worldwide. Serological testing for SARS-CoV-2-spe...
Murine IgA binding factors (IgA-BF) suppressing IgA production: characterization and target specificity of IgA-BF.
Murine IgA binding factors (IgA-BF) suppressing IgA production: characterization and target specificity of IgA-BF.
Abstract Chemical and functional properties of IgA binding factor(s) (IgA-BF) from both murine Con A-activated spleen cells and Fc gamma R+, Fc alpha R+ T hybridoma ...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines
Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines
AbstractVaccines that elicit mucosal immune responses against SARS-CoV-2 could potentially be of exceptional importance in providing first line defense at the site of viral entry. ...
Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays
Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays
AbstractSerologic testing for SARS-CoV-2 antibodies can be used to confirm diagnosis, estimate seroprevalence, screen convalescent plasma donors, and assess vaccine efficacy. Sever...
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
AbstractBackgroundSevere acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is an emerging disease with fatal outcomes. In this study, a fundamental knowledge gap question is to...

Back to Top